Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | PRKCA | P17252 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8183533 | 1.00 | SMN1; SMN2 (0.37) | SMN1; SMN2SUCNR1GAAALDH1A1PRKCA | |
| SCHEMBL6249176 | 1.00 | SMN1; SMN2 (0.37) | SMN1; SMN2SUCNR1GAAALDH1A1PRKCA | |
| SCHEMBL14867340 | 1.00 | SMN1; SMN2 (0.37) | SMN1; SMN2SUCNR1GAAALDH1A1PRKCA | |
| SCHEMBL6252053 | 1.00 | SMN1; SMN2 (0.37) | SMN1; SMN2SUCNR1GAAALDH1A1PRKCA | |
| SCHEMBL19788605 | 1.00 | SMN1; SMN2 (0.37) | SMN1; SMN2SUCNR1GAAALDH1A1PRKCA | |
| SCHEMBL8039345 | 0.85 | SMN1; SMN2 (0.38) | SMN1; SMN2GAAALDH1A1PRKCAKDM4E | |
| SCHEMBL8040037 | 0.85 | SMN1; SMN2 (0.38) | SMN1; SMN2GAAALDH1A1PRKCAKDM4E | |
| SCHEMBL8050829 | 0.85 | SMN1; SMN2 (0.38) | SMN1; SMN2GAAALDH1A1PRKCAKDM4E | |
| SCHEMBL7907083 | 0.81 | USP2 (0.38) | SMN1; SMN2GAAALDH1A1PRKCAKDM4E | |
| SCHEMBL7904533 | 0.81 | USP2 (0.38) | SMN1; SMN2GAAALDH1A1PRKCAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8968711-B2 | Cosmetic or dermatological composition comprising a polymer bearing junction groups, and cosmetic treatment process | L'OREAL (FR) | 2015-03-03 | — | — | US | claimed |
| US-20100272660-A1 | COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT | L'OREAL (FR) | 2010-10-28 | — | — | US | claimed |
| US-20100239509-A1 | COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT PROCESS | L'OREAL (FR) | 2010-09-23 | — | — | US | claimed |
| US-20070007489-A1 | Heat transfer medium composition | SHISHIAI-KABUSHIKIGAISHA (JP) | 2007-01-11 | — | — | US | claimed |
| EP-1698678-A1 | HEAT CARRIER COMPOSITION | Shishiai-Kabushikigaisha (JP) | 2006-09-06 | — | — | EP | claimed |
| US-5683793-A | Ink jet transparencies | XEROX CORPORATION (US) | 1997-11-04 | — | — | US | claimed |
| US-5589277-A | INK JET PRINTING, AQUEOUS INKS, FAST DRYING | XEROX CORPORATION (US) | 1996-12-31 | — | — | US | claimed |
| EP-0667246-A1 | Recording sheets containing amino acids, hydroxy acids, and polycarboxyl compounds | XEROX CORPORATION (US) | 1995-08-16 | — | — | EP | claimed |
| EP-4619386-A1 | ARYL THIOETHERS AS HIF-2ALPHA INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2025-09-24 | — | — | EP | disclosed |
| CN-119868281-B | Dental pulp stem cell-containing repairing injection and preparation method thereof | 新北辰(湖北)生物科技集团有限公司 | 2025-06-24 | — | — | CN | disclosed |
| CN-119868281-A | Dental pulp stem cell-containing repairing injection and preparation method thereof | 新北辰(湖北)生物科技集团有限公司 | 2025-04-25 | — | — | CN | disclosed |
| WO-2024104932-A1 | ARYL THIOETHERS AS HIF-2ALPHA INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2024-05-23 | — | — | WO | disclosed |
| US-9872514-B2 | Compounds, compositions, and methods for reducing or eliminating bitter taste | CHROMOCELL CORPORATION (US) | 2018-01-23 | — | — | US | disclosed |
| US-9872514-B2 | Compounds, compositions, and methods for reducing or eliminating bitter taste | CHROMOCELL CORPORATION (US) | 2018-01-23 | — | — | US | disclosed |
| US-5683793-A | Ink jet transparencies | XEROX CORPORATION (US) | 1997-11-04 | — | — | US | disclosed |
| US-5643958-A | ANTITUMOR | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1997-07-01 | — | — | US | disclosed |
| EP-0776884-A1 | SUBSTITUTED AMIDE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1997-06-04 | — | — | EP | disclosed |
| WO-1997001275-A1 | COMBINATIONS OF INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1997-01-16 | — | — | WO | disclosed |
| US-5589277-A | INK JET PRINTING, AQUEOUS INKS, FAST DRYING | XEROX CORPORATION (US) | 1996-12-31 | — | — | US | disclosed |
| EP-0667246-A1 | Recording sheets containing amino acids, hydroxy acids, and polycarboxyl compounds | XEROX CORPORATION (US) | 1995-08-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100239509-A1 | COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT PROCESS | CUTA, SUCLG1, KRT18 | SMN1; SMN2 4595/4885SUCNR1 291/4885GAA 342/4885 |
| US-20100272660-A1 | COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT | ACMSD, CUTA, PCCA | SMN1; SMN2 3730/4885SUCNR1 52/4885GAA 654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.